Please ensure Javascript is enabled for purposes of website accessibility

Investor sues Emergent BioSolutions for alleged fraud, seeks class action (access required)

Emergent BioSolutions Inc.’s ruination of 15 million doses of COVID-19 vaccine at its Baltimore plant was not as unexpected as the Gaithersburg-based company would have the public believe, an investor has alleged in a potential class-action lawsuit accusing the business of having committed securities fraud. Alan I. Roth claims Emergent knew the federal government was concerned ...

To purchase a reprint of this article, contact [email protected].